Exelixis (EXEL) Stock Price, News & Analysis

Company Overview

Exelixis, Inc. is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer. In addition, Exelixis markets TURALIO® (pexidartinib), a first-in-class colony-stimulating factor-1 receptor (CSF1R) inhibitor indicated for symptomatic tenosynovial giant cell tumor. Exelixis maintains a diverse pipeline of targeted oncology candidates, several of which are in mid-to-late-stage clinical trials exploring indications such as prostate cancer and ovarian cancer.

Headquartered in Alameda, California, Exelixis operates research and development facilities in the United States and collaborates with international partners to extend its global reach. The company has a strategic commercialization alliance with Ipsen for territories outside the United States, and it engages in collaborations with other pharmaceutical and biotech firms to expand its portfolio and access complementary technologies. Exelixis’s products are available in North America, Europe, and select Asian markets.

Founded in 1994, Exelixis went public in 2000 and has since evolved into a leader in oncology drug discovery and development. The company is led by President and Chief Executive Officer Michael M. Morrissey, whose tenure has emphasized pipeline growth and global commercialization. Under his leadership, Exelixis continues to invest in research initiatives, clinical development programs and strategic partnerships aimed at bringing new cancer therapies to patients worldwide.

Key Stats

• Today's Range: $35.44 to $36.45
• 50-Day Range: $34.54 to $41.35
• 52-Week Range: $27.86 to $49.62
• Volume: 1.71 million shs
• Average Volume: 2.96 million shs
• Market Capitalization: $9.79 billion
• P/E Ratio: 17.48
• Dividend Yield: N/A
• Price Target: $44.53
• Consensus Rating: Moderate Buy

Exelixis Stock Analysis - MarketRank™

Exelixis scored higher than 97% of companies evaluated by MarketBeat, and ranked 24th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Exelixis has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 14 buy ratings, 10 hold ratings, and no sell ratings.

Upside Potential

Exelixis has a consensus price target of $44.53, representing about 22.4% upside from its current price of $36.39.

Amount of Analyst Coverage

Exelixis has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 25.00%

Earnings Growth

Earnings for Exelixis are expected to grow by 25.00% in the coming year, from $2.04 to $2.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exelixis is 17.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 79.34.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exelixis is 17.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.65.

Price to Earnings Growth Ratio

Exelixis has a PEG Ratio of 0.69. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Exelixis has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.81% of the float of Exelixis has been sold short.

Short Interest Ratio / Days to Cover

Exelixis has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Exelixis has recently increased by 0.91%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exelixis does not currently pay a dividend.

Dividend Growth

Exelixis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.63

Percentage of Shares Shorted

6.81% of the float of Exelixis has been sold short.

Short Interest Ratio / Days to Cover

Exelixis has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Exelixis has recently increased by 0.91%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.35

News Sentiment

Exelixis has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 38 news articles for Exelixis this week, compared to 22 articles on an average week.

Search Interest

24 people have searched for EXEL on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

9 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exelixis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.82% of the stock of Exelixis is held by insiders.

Percentage Held by Institutions

85.27% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EXEL Stock Analysis - Frequently Asked Questions

How have EXEL shares performed this year?

Exelixis' stock was trading at $33.30 on January 1st, 2025. Since then, EXEL stock has increased by 9.3% and is now trading at $36.39.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings data on Monday, July, 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. The firm's revenue was down 10.8% on a year-over-year basis.
Read the conference call transcript.

Who are Exelixis' major shareholders?

Exelixis' top institutional shareholders include Pacer Advisors Inc. (0.48%), Allspring Global Investments Holdings LLC (0.43%), Robeco Institutional Asset Management B.V. (0.36%) and Assenagon Asset Management S.A. (0.26%). Insiders that own company stock include David Edward Johnson, Stelios Papadopoulos, Christopher J Senner, Jeffrey Hessekiel, Dana Aftab, Amy C Peterson, Patrick J Haley, Peter Lamb, Jack L Wyszomierski, George Poste, Maria C Freire, Maria C Freire, Alan M Garber, Bob Oliver, Tomas J Heyman, Mary C Beckerle, Sue Gail Eckhardt and Carl B Feldbaum.
View institutional ownership trends.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exelixis investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Humana (HUM), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 7/28/2025
• Today: 10/22/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EXEL
• CIK: 939767
• Web: www.exelixis.com
• Phone: (650) 837-7000
• Fax: 650-837-8300
• Employees: 1,147
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Exelixis: $44.53
• High Price Target: $60.00
• Low Price Target: $30.00
• Potential Upside/Downside: +23.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.08
• Trailing P/E Ratio: 17.37
• Forward P/E Ratio: 17.71
• P/E Growth: 0.69
• Net Income: $521.27 million
• Net Margins: 27.01%
• Pretax Margin: 34.78%
• Return on Equity: 27.47%
• Return on Assets: 20.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.51
• Quick Ratio: 3.44

Sales & Book Value

• Annual Sales: $2.17 billion
• Price / Sales: 4.48
• Cash Flow: $2.02 per share
• Price / Cash Flow: 17.93
• Book Value: $7.86 per share
• Price / Book: 4.60

Miscellaneous

• Outstanding Shares: 269,200,000
• Free Float: 261,531,000
• Market Cap: $9.73 billion
• Optionable: Optionable
• Beta: 0.38